Novo Nordisk : NVO

NVO

Stock Data

$60.68

$1.65 (2.65%)

Asset Type

Common Stock

Exchange

NYSE

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

DRUG MANUFACTURERS - GENERAL

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

All Novo Nordisk Articles

129 Articles

Ian Cooper | Dec 24, 2025 at 9:47 AM EST

Stock Market Live December 24, 2025: S&P 500 (SPY) at Record Highs

With the holidays upon us, markets aren’t moving much.Instead, many are taking time off to enjoy the holidays and their…

Rich Duprey | Dec 23, 2025 at 1:23 PM EST

Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly’s Looming Pill?

Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk‘s (NYSE:NVO) Wegovy weight-loss pill, the first of its kind. This…

Ian Cooper | Dec 23, 2025 at 8:58 AM EST

Premarket Movers: Albemarle Gaining Momentum on Lithium Boom

Albemarle (NYSE: ALB) had an incredible year.Since bottoming out at around $50 in April, the lithium giant exploded to $145.38.…

Joel South | Dec 21, 2025 at 8:25 AM EST

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2026-2030 (Dec 2025)

Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. With promising new treatments in the pipeline,…

Douglas A. McIntyre | Nov 14, 2025 at 4:13 PM EST

Retail Investors Really Don’t Like Novo Nordisk (NVO) Stock

Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of…

Omor Ibne Ehsan | Nov 11, 2025 at 10:07 AM EST

3 Buy-And-Forget Dividend Stocks With Snowballing Payouts

If the headline yield today is not something you’re concerned with, and you pay more attention to how fast a…

Trey Thoelcke | Nov 5, 2025 at 8:45 AM EST

Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More

In the past week or so, a biotech and an energy infrastructure giant saw some huge insider buying. These were…

Rich Duprey | Nov 3, 2025 at 10:13 AM EST

Viking Therapeutics Could Be Pharma’s Next Big Buyout Target

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that…

Rich Duprey | Oct 22, 2025 at 11:48 AM EDT

Market Meltdown Coming? These 2 ETFs Are Ready to Surge If Stocks Tank

The U.S. stock market has delivered impressive gains for over a decade, but warning signs of a potential downturn are…

Rich Duprey | Oct 17, 2025 at 11:05 AM EDT

Is Trump Going to Kill the GLP-1 Cash Cow?

The Boom That Built Billion-Dollar EmpiresGLP-1 drugs have reshaped the pharmaceutical landscape, turning obesity and diabetes treatments into massive revenue…